Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

Drug (Brand / Generic)

Kisqali / ribociclib

Developer

Novartis

Product Description

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor

Current Indication

Metastatic breast cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top